[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-arrythmias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-arrythmias":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,63,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100289852","rhythmia-mapping-and-signal-acquisition-for-data-analysis-rhapsody-100289852",false,"NCT03053141","RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)","RHAPSODY","Inclusion Criteria:\n\n1. Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law\n2. Scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.\n\nExclusion Criteria:\n\n1. Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia\n2. Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy, etc.)\n3. Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route\n4. Active systemic infection or sepsis\n5. Hemodynamic instability or shock at baseline precluding ablation in the assessment of the investigator.\n6. Presence of intracardiac thrombus, tumor, or other abnormality which precludes catheter introduction\n7. Women who are pregnant or lactating\n8. Cardiac surgery within the past 90 days\n9. Acute myocardial infarction within 3 months\n10. Stable\u002Funstable angina or ongoing myocardial ischemia\n11. Subjects with an active heart failure decompensation\n12. Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes\n13. Congenital heart disease with or without corrective surgery that would complicate a mapping procedure\n14. Subjects having untreatable allergy to contrast media\n15. Vascular pathology or tortuosity precluding standard vascular access techniques\n16. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.",[24],"Cardiac Arrythmias","RECRUITING","2026-06-29",{"date":28,"type":29},"2026-06-30","ACTUAL",{"date":31,"type":29},"2016-05",{"date":33,"type":20},"2027-12",{"name":35,"class":36},"Boston Scientific Corporation","INDUSTRY",8,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100620732","agilis-rf-tsp-early-feasibility-study-100620732","NCT07361445","Agilis RF TSP Early Feasibility Study","Agilis Radiofrequency Transseptal System Early Feasibility Study","Inclusion Criteria:\n\n* Is able and willing to provide written informed consent prior to any clinical investigation-related procedure\n* Plans to undergo an ablation procedure in LA, LV or concomitant procedure with ablation and LAAO device implantation requiring transseptal puncture\n* Is at least 18 years of age\n* Able and willing to comply with all study requirements\n\nExclusion Criteria:\n\n* Currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from the study Sponsor\n* Pregnant or nursing\n* Known presence of intracardiac thrombus\n* Known existing circumferential pericardial effusion (\\>2 mm)\n* Previous interatrial septal patch or prosthetic atrial septal defect closure device\n* Any previous thromboembolic event with in the last 6 months\n* Known or suspected left atrial myxoma\n* Known or suspected myocardial infarction within the last two weeks\n* Unstable angina\n* Recent (within the last 3 months) cerebral vascular accident (CVA)\n* Patients with an active infection\n* Patients who do not tolerate anticoagulation therapy\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results",{"count":46,"type":20},60,"INTERVENTIONAL",[49],"NA","This study is a prospective, acute, first-in-human, early feasibility study intended to assess the initial safety and performance of the Agilis™ Radiofrequency (RF) Transseptal (TSP) System in crossing the atrial septum for left atrial and left ventricular access during cardiac electrophysiology (EP) and interventional cardiology (IC) procedures. This study will be conducted in an acute setting. Subjects will be followed through hospital discharge, and no follow-up visits will be required for this study.",[24,52],"Left Atrial Appendage Closure","2026-05-29",{"date":55,"type":29},"2026-06-02",{"date":57,"type":29},"2026-02-16",{"date":59,"type":20},"2026-08-03",{"name":61,"class":36},"Abbott Medical Devices",3,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100639659","minimally-invasive-hemodynamic-monitoring-in-cardiac-ablation-100639659","NCT07603765","Minimally Invasive Hemodynamic Monitoring in Cardiac Ablation","Prospective Clinical Study of Minimally Invasive Hemodynamic Monitoring Outcomes in Cardiac Ablation Procedures","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients scheduled for cardiac catheter ablation in the electrophysiology laboratory\n* Indication for ablation confirmed by a cardiologist\n* Ability to provide written informed consent\n* Planned invasive arterial blood pressure monitoring during the procedure\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* Failure to identify arrhythmogenic focus leading to cancellation of ablation procedure\n* Severe hemodynamic instability prior to procedure\n* Contraindication to invasive arterial catheterization\n* Incomplete hemodynamic data acquisition\n* Pregnancy",{"count":71,"type":20},27,"This prospective observational clinical study aims to evaluate the clinical utility of Pressure Recording Analytical Method (PRAM)-based minimally invasive hemodynamic monitoring in patients undergoing cardiac ablation procedures. The study will be conducted in the cardiac catheterization laboratory of Istanbul University-Cerrahpaşa Cardiology Institute and will include 27 adult patients scheduled for catheter ablation. Written informed consent will be obtained from all participants, and the study will adhere to the principles of the Declaration of Helsinki.",[24,74],"Anesthesia",[76,77,78,79,80],"catheter ablation","anesthesiology","conscious Sedation","deep sedation","hemodynamic monitoring","2026-05-21",{"date":83,"type":29},"2026-05-22",{"date":85,"type":29},"2026-04-30",{"date":87,"type":20},"2026-12-15",{"name":89,"class":90},"Istanbul University - Cerrahpasa","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":91},"100587626","frailty-classification-algorithm-for-the-corsano-cardiowatch-287-2-a-development-and-validation-study-100587626","NCT06930833","FRAILTY Classification Algorithm for the Corsano CARDIOWATCH 287-2: a Development and Validation Study","FRAILTY-CW2","Inclusion Criteria:\n\n* ≥ 70 years old\n* Be able to provide consent\n* Be scheduled to undergo one of the following procedures:\n\n  * Aortic valve replacement\n  * Mitral valve repair with MitraClip\n  * Implantation of a pacemaker\n  * Percutaneous coronary intervention (PCI)\n\nExclusion Criteria:\n\n* Unable to wear the Corsano CardioWatch 287-2 due to reasons such as allergic reactions, wounds, amputations etc.;\n* Unable or unwilling to sign informed consent;\n* Significant mental or cognitive impairment;\n* Cardiovascular disease where heart rate is not measurable (e.g. LVAD)","70 Years",{"count":101,"type":20},20,"The FRAILTY-CARDIOWATCH study is investigating how well the Corsano CardioWatch 287-2, a wrist-worn medical device, can classify frailty in patients. Frailty is a condition often seen in older adults, characterized by decreased strength, endurance, and overall health, which can make individuals more vulnerable to illness or injury. The goal of this study is to develop an algorithm that can accurately assess frailty using the device. In phase 1 of the study, data will be collected from patients aged 70 or older who are scheduled for heart-related procedures, such as valve replacements or pacemaker implantation.\n\nThe study aims to compare the frailty classifications of the CardioWatch with two established methods: the Geriatric 8 (G8) questionnaire and the FRAIL scale. It will also compare the CardioWatch with the 6-minute walk test. Patients will wear the CardioWatch for six days-three days before their procedure and three days after-and complete the G8, FRAIL, and 6-minute walk tests. The collected data will help develop and train the frailty classification algorithm.\n\nThe main focus is to evaluate how well the frailty classifications from the CardioWatch match those from the other tests. This research could potentially lead to a more accurate and continuous way to monitor frailty in patients using wearable technology.",[24,104,105],"Valve Heart Disease","Cardiac Ischemia",[107,108,109,110,111,112,113],"Frailty","6-minute walking test","G8-score","wristband","wearable","remote monitoring","cardiac surgical interventions","NOT_YET_RECRUITING","2025-04-16",{"date":117,"type":29},"2025-04-20",{"date":119,"type":20},"2025-05",{"date":121,"type":20},"2026-10",{"name":123,"class":36},"Corsano Health B.V."]